

Study Group Prostate Cancer – PiR-hoP project

PiR-hoP aims at developing a multi-site prostate cancer registry for two distinct, especially challenging prostate cancer patient groups, those with an oligometastatic tumor and those of young age with a high risk cancer

Speaker: Prof. Dr. Bernd Wullich, Erlangen

Authors: All members of the Study Group

Concept & Achievements


Background

PiR-HoP aims at establishing a multi-site prospective clinical registry for two specific groups of prostate cancer patients, who present a particular clinical challenge:

- » the oligometastatic prostate cancer
- » the high risk prostate cancer in young patients

For both patient groups there are no uniform evidence-based treatment recommendations in the guidelines.


As only relatively few of these patients are managed at each center, there is a great opportunity in the association of university centers in Bavaria to derive relevant conclusions from aggregated data on these patients. All requests for cross-site scientific evaluations will be checked by the appointed steering committee and approved in a voting procedure. This procedure is regulated in the privacy concept..



Project framework

Work packages and achievements

WP	Title	Result	Responsibility	Successfully completed
1, 4	Selection of EDC system	Secutrial	E, LMU, TU	✓
2	Defining the clinical dataset		A, TU, W	✓
3	Developing a privacy concept		E, R	✓
3	Developing a patient consent form		E, R	in coordination
5	Developing of a standardized reporting system for advanced imaging		R, TU	✓
6	Programming of the database and iterative testing	Clinical registry prototype	A, E, TU	✓



BZKF networking and interaction

Future Milestones

- » Start of multi-site documentation of real-life clinical care
- » Evaluation of the PROMISE V2 framework for structured reporting of PET/CT findings as a prognosticator of patient outcome and therapy decisions
- » Evaluation of the value of local primarius-directed therapies
- » Evaluation of the value of local metastasis-directed therapies
- » Evaluation of the value of multimodal therapies
- » Liquid biopsy sampling and establishment of a highly standardized and quality-assured workflow
- » Promotion of a BZKF-wide module Z for the Broad Consent of the MII